Skip to content

Based on the Leukotriene Pathway to Explore the Efficacy and Mechanism of Jiawei Yupingfeng Nasal Irrigation in the Treatment of Patients with Allergic Rhinitis

Based on the Leukotriene Pathway to Explore the Efficacy and Mechanism of Jiawei Yupingfeng Nasal Irrigation in the Treatment of Patients with Allergic Rhinitis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200058946
Enrollment
Unknown
Registered
2022-04-20
Start date
2022-05-01
Completion date
Unknown
Last updated
2024-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Rhinitis

Interventions

Group 1:Jiawei Yupingfeng Nasal Irrigation
Group 2:Nasal Irrigation with Sodium Chloride Saline
Group 3:Budesonide Nasal Irrigation

Sponsors

Xiyuan Hospital, Chinese Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Symptoms: 2 or more symptoms such as sneezing, runny nose, nasal itching, and nasal congestion, which last for more than 1 hour a day, or accompanied with eye symptoms such as itching, tearing and redness; 2. Signs: Pale nasal mucosa, edema, watery nasal discharge; 3. Allergen test: At least one skin prick or serum specific IgE is positive; 4. Agree to accept treatments and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Long-term smoking history; 2. Patients with acute upper and lower respiratory tract infections; 3. Patients with asthma; 4. Received any treatments of nasal spray or irrigation for allergic rhinitis within 1 week before the study; 5. Patients with severe hypertension, diabetes or liver and kidney diseases; 6. Pregnant and lactating patients; 7. Combined with severe nasal septum deviation, otitis media and other patients who are not suitable for nasal irrigation; 8. Patients who are allergic to Chinese medicine granules; 9. Failure to comply with the experimental protocol, or other circumstances that the investigator does not consider suitable for inclusion.

Design outcomes

Primary

MeasureTime frame
Visual Analogue Scale of Nasal Symptoms;

Secondary

MeasureTime frame
Inflammation mediator of nasal secretion;Lund-Kenndy Nasal Endoscopy Score;

Countries

China

Contacts

Public ContactFeng Wei
13611147987@163.com+86 13611147987

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026